Filing Flows › Comparisons › ABBV vs SNY
AbbVie vs Sanofi: ABBV and SNY compared
AbbVie is the larger company: $17.4B of revenue in its latest quarter (Q3 2026) against $14.4B for Sanofi (Q3 2026). Sanofi is growing faster (+16% against +10% a year earlier). AbbVie is more profitable, with an operating margin of 36.0% against 30.1%.
Where the money goes: ABBV and SNY
AbbVie (ABBV) · Q3 2026
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart follows the revenue to costs, profit and cash.
Sanofi (SNY) · Q3 2026
Sanofi, Q3 2026: revenue $14.4B (+16% year over year), operating margin 30.1%, net earnings $3.0B. The chart follows the revenue to costs, profit and cash.
| AbbVie (ABBV) | Sanofi (SNY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $17.4B | $14.4B |
| Revenue growth, Y/Y | +10% | +16% |
| Gross margin | — | 80.3% |
| Operating margin | 36.0% | 30.1% |
| Net earnings | $4.2B | $3.0B |
| Net margin | 24.2% | 21.0% |
| Operating cash flow | $7.6B | — |
| Free cash flow | $7.3B | — |
| Market value | $516.2B | — |
| P/E | 50.1× | — |
| Analysts’ mean target | $310.65 | — |
Where the revenue comes from
Sanofi
- Sales at constant exchange rates: $14.2B (98%)
- Effect of exchange rates: $228M (2%)
Questions
Which is bigger, AbbVie or Sanofi?
AbbVie is the larger company: $17.4B of revenue in its latest quarter (Q3 2026) against $14.4B for Sanofi (Q3 2026).
Is AbbVie or Sanofi growing faster?
Sanofi is growing faster (+16% against +10% a year earlier).
Which is more profitable, AbbVie or Sanofi?
AbbVie is more profitable, with an operating margin of 36.0% against 30.1%.
More: AbbVie earnings · how AbbVie makes money · Sanofi earnings · how Sanofi makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 6-K filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.